PharmaNet Development Group, Inc. (NASDAQ: PDGI) today announced that
Jeffrey P. McMullen, president and chief executive officer, will make a
presentation on the Company at the Bank of America 2008 Smid Cap
Conference on Wednesday March 26, 2008 at 10:30 am EST. The conference
will take place at the Four Seasons, Boston, MA.
A live audio webcast of the presentation will be accessible from the
investor tab of the Company web site at www.pharmanet.com.
The replay of the webcast is expected to be available approximately one
hour after the live presentation and will be available through Friday
April 11, 2008 on the Company web site.
About PharmaNet Development Group,
Inc.
PharmaNet Development Group, Inc., a global drug development services
company, provides a comprehensive range of services to the
pharmaceutical, biotechnology, generic drug, and medical device
industries. The Company offers clinical-development solutions including
early and late stage consulting services, Phase I clinical studies and
bioanalytical analyses, and Phase II, III and IV clinical development
programs. With approximately 2,600 employees and more than 44 facilities
throughout the world, PharmaNet is a recognized leader in outsourced
clinical development. For more information, please visit our website at www.pharmanet.com.
Forward-Looking Statements
Certain statements made in this press release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the "Act"). Additionally, words such as "seek,"
"intend," "believe," "plan," "estimate," "expect," "anticipate" and
other similar expressions are forward-looking statements within the
meaning of the Act. Some or all of the results anticipated by these
forward-looking statements may not occur. Factors that could cause or
contribute to such differences include, but are not limited to, industry
trends and information; the Company's ability to determine its
impairment charges and costs of discontinued operations; whether the
Company will achieve its estimated value relating to discontinued
operations; developments with respect to the SEC's inquiry and
securities class action lawsuits and derivative lawsuits (Due to the
inherent uncertainties of litigation, the reserve for the litigation is
only an estimate. Management may need to adjust the reserve in the
future as outcomes of the securities class action and other related
litigation becomes more predictable); the Company’s
ability to successfully achieve and manage the technical requirements of
specialized clinical trial services, while complying with applicable
rules and regulations; regulatory changes; changes affecting the
clinical research industry; a reduction of outsourcing by pharmaceutical
and biotechnology companies; the Company’s
ability to compete internationally in attracting clients in order to
develop additional business; the Company’s
evaluation of its backlog and the potential cancellation of contracts;
its ability to retain and recruit new employees; its clients' ability to
provide the drugs and medical devices used in its clinical trials; the
Company’s future stock price; the Company’s
assessment of its effective tax rate and tax allowance; the Company’s
financial guidance; the Company’s future
effective tax rate; the Company’s anticipated
capital expenditures; the Company’s costs
associated with compliance of Section 404 of the Sarbanes-Oxley Act; the
impact on the Company of foreign currency transaction costs and the
effectiveness of any hedging strategies it implements; and the national
and international economic climate as it affects drug development
operations.
Further information can be found in the Company’s
risk factors contained in its Annual Report on Form 10-K for the year
ended December 31, 2006 and its most recent Quarterly Report on Form
10-Q. The Company does not undertake to update the disclosures made
herein, and you are urged to read our filings with the Securities and
Exchange Commission.
Bookmarken
